Transdermal Application of H100 Gel to the Penile Shaft in Patients with Peyronie's Disease Infiltrates the Tunica Albuginea - Beyond the Abstract ...

Robotic versus Open Cystectomy with Ileal Conduit for the Management of Neurogenic Bladder: A Comparative Study - Beyond the Abstract ...

Does Adjuvant Immune Checkpoint Inhibition Therapy Have a Future in Operable Bladder Cancer? December 18, 2025 Real-World Comparison of Survival Outcomes Between Radical Cystectomy and Intravesical ...

Antioxidants for Male Infertility: Therapeutic Scheme and Indications. A Retrospective Single-Center Real-Life Study - Beyond the Abstract ...

Robotic/laparoscopic prolapse repair and the role of hysteropexy: A urology perspective, "Beyond the Abstract," by Daniel S. Elliott, MD ...

Therapeutic Advances in Metastatic Prostate Cancer: A Journey from Standard of Care to New Emerging Treatment. December 12, 2025 Predicting Toxicities and Survival Outcomes in De Novo Metastatic ...

Daniel Spratt and Alicia Morgans discuss clinical outcomes of patients with Gleason score 9-10 prostate cancer after definitive treatment. Long-term Survival in Men with Gleason Score 9-10 Treated ...

Pedro Barata interviews Wen Kong about lenvatinib plus tislelizumab for first-line treatment of fumarate hydratase (FH)-deficient renal cell carcinoma. Dr. Kong shares results from a single-center ...

Tamara Lotan delves into the evolution of pathology in the realm of urologic oncology, emphasizing the integration of digital and AI technologies. Dr. Lotan highlights how digital pathology, ...

Ashish Kamat interviews Patrick Soon-Shiong about the approval of Anktiva for bladder cancer treatment. Dr. Soon-Shiong shares his journey from pancreatic surgery at UCLA to developing this innovative ...

Marco Moschini joins Sam Chang in a discussion on highlighting a European Urology Oncology publication that sought to review the available literature systematically focused on incidence, diagnosis, ...

Zachary Klaassen and Amanda Myers discuss a single-institution study examining response rates to additional BCG therapy in high-risk non-muscle invasive bladder cancer patients. Dr. Myers presents ...